Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06562608 · ClinicalTrials.gov registry record · Phase 4
Anticholinergic Deprescription in Schizophrenia
A Phase 4 study of Schizophrenia and Schizoaffective Disorder, sponsored by Deepak K. Sarpal, M.D..
- Recruiting
- Registry status
- Phase 4
- Development phase
- 105
- Enrollment target
- 1
- Study location
NCT06562608 is a Phase 4 study of Schizophrenia and Schizoaffective Disorder that is actively recruiting participants, run by Deepak K. Sarpal, M.D.. The registered enrollment target is 105 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06562608, a Phase 4 study of Schizophrenia and Schizoaffective Disorder, is actively recruiting participants, sponsored by Deepak K. Sarpal, M.D..
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 105 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, the investigators will examine whether a deprescription of unnecessary anticholinergic drugs (benztropine or trihexyphenidyl) can augment quality of life, functioning, and neurocognition in individuals who with schizophrenia. Individuals identified by clinical services who have unneeded prescriptions benztropine or trihexyphenidyl will be eligible for deprescription and study entry. Following a baseline evaluation and magnetic resonance imaging (MRI), participants will will be randomized to either staying on their anticholinergic drugs or undergoing deprescription per routine clinical care, and will undergo follow-up evaluations across 6 months. The investigators predict that reducing and deprescribing these drug, if clinically determined to be unnecessary will will enhance functioning, neurocognition
Conditions Studied
Interventions
- DRUG Anticholinergic Deprescription
- DRUG No Anticholinergic Deprescription
Study Locations (1)
Pennsylvania
- UPMC Western Psychiatric Hospital/University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2025-02-01 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06562608
The ClinicalTrials.gov registry entry for NCT06562608 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (52% lower). The listed sponsor is Deepak K. Sarpal, M.D., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Anticholinergic Deprescription is the first listed.
NCT06562608 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06562608 about?
NCT06562608 is a clinical study titled "Anticholinergic Deprescription in Schizophrenia". In this study, the investigators will examine whether a deprescription of unnecessary anticholinergic drugs (benztropine or trihexyphenidyl) can augment quality of life, functioning, and neurocognition in individuals who with schizophrenia. Individuals identified by clinical services who have unneed...
What is the current status of trial NCT06562608?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 105 participants. The study started on 2025-02-01. Estimated completion is 2029-06-30.
What conditions does trial NCT06562608 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
What interventions are being tested in trial NCT06562608?
The interventions under investigation include: Anticholinergic Deprescription (DRUG), No Anticholinergic Deprescription (DRUG).
Who is sponsoring clinical trial NCT06562608?
This trial is sponsored by Deepak K. Sarpal, M.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06562608 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.